Drug intelligence / Profile preview

DRD2 peptide

Development stage: Preclinical
Lead developer: AecorBio
Modality: Peptides

Overview

DRD2 peptide is a preclinical-stage therapeutic candidate being developed by AecorBio for the treatment of Parkinson's disease and Restless Leg Syndrome. The drug is a peptide designed to target and modulate the Dopamine receptor D2 (DRD2). By acting as an agonist or modulator of these receptors, the peptide aims to restore dopaminergic signaling, which is characteristically impaired in both Parkinson's disease and Restless Leg Syndrome. As a peptide-based modality, it may offer enhanced specificity and a different safety profile compared to traditional small-molecule dopamine agonists commonly used for these neurological conditions.

Other names: Peptide-DRD2-AecorBio-DRD2-peptide-Restless Leg Syndrome-Parkinson's Disease

Targets

DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on DRD2 peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DRD2 peptide.

Explore the full profile